BRING THIS TO YOUR DOCTOR · GREY PEPTIDES

Pegcetacoplan

Also called: Empaveli; Syfovre; APL-2

What it is

A pegylated peptide C3 inhibitor approved as Empaveli (2021) for PNH and C3 glomerulopathy, and as Syfovre (2023) for geographic atrophy in macular degeneration.

Approval status

FDA Approved. Approved in the US as Empaveli (pegcetacoplan), NDA 215014, on May 14, 2021, for PNH, with a later indication for C3 glomerulopathy and primary IC-MPGN; and as Syfovre, NDA 217171, on February 17, 2023, for geographic atrophy (Drugs@FDA via openFDA and both labels, read October 3, 2026). Empaveli carries a boxed warning for serious infections caused by encapsulated bacteria and is available only through a REMS.

Dosing, as printed in the page's Recommended Dosing box

Manufacturer's recommended dosing (FDA label)

From the prescribing information. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Empaveli: PNH, C3G and IC-MPGN (adults) **[Approved label]** Empaveli prescribing information, section 2 (DailyMed set c23d89e9, version 14, effective August 21, 2026)	1,080 mg	Twice weekly	Ongoing	Subcutaneous infusion
Syfovre: geographic atrophy **[Approved label]** Syfovre prescribing information, section 2 (DailyMed set b4434e61, version 12, effective September 16, 2025)	15 mg (0.1 mL) per eye	Every 25 to 60 days	Ongoing	Intravitreal

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 9 human studies carded on the page (12 study cards in all):

• **PEGASUS: against eculizumab in PNH** (Human, 2021). In 80 adults still anaemic on eculizumab, pegcetacoplan raised haemoglobin by 3.84 g/dL more by week 16, and 85% against 15% no longer needed transfusions. Injection-site reactions (37% against 3%) were more common, breakthrough haemolysis less common. **PMID 33730455**

• **Three years in PNH** (Human, 2025). Across PEGASUS, PRINCE and their extension, haemoglobin and fatigue stayed near normal for up to three years, with yearly transfusion avoidance of 71% to 86%; breakthrough haemolysis occurred in 28%. **PMID 40720060**

• **PNH with milder anaemia** (Human, 2024). In 25 patients whose haemoglobin was already 10 g/dL or more, 16 weeks raised it to about 12.7 to 14.0 g/dL. **PMID 39079163**

Interactions

A PubMed search for interaction studies of this compound with any drug (October 3, 2026, 0 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• Injection-site reactions and diarrhoea (Empaveli) • Breakthrough haemolysis in PNH • New wet macular degeneration (Syfovre)	• Boxed warning: serious infections caused by encapsulated bacteria; vaccination required, and Empaveli is available only through a REMS • Monitoring for PNH manifestations after stopping Empaveli • Interference with some laboratory tests • Syfovre: endophthalmitis, retinal detachment, retinal vasculitis or vascular occlusion, wet macular degeneration, intraocular inflammation and raised eye pressure

Five questions to ask

1. Is Pegcetacoplan right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Pegcetacoplan? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example injection-site reactions and diarrhoea?
4. Do any of the cautions on this sheet apply to me, such as: Boxed warning: serious infections caused by encapsulated bacteria?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.